Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights
BEDFORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2022, and highlighted recent accomplishments
By Homology Medicines, Inc.
Published - Nov 10, 2022, 04:15 PM ET
Last Updated - Apr 24, 2024, 01:10 PM EDT
- On Track for Updates on pheEDIT and juMPStart Programs by Year-End -
- Strong Financial Position with Cash Runway into Fourth Quarter 2024 -
- Promoted Albert Seymour, Ph.D., to Chief Executive Officer Driving Clinical Trials and Genetic Medicines Platform Forward for Patients -
BEDFORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2022, and highlighted recent accomplishments.
